AG
REGN icon

Artal Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Artal Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,000
Closed -$20.1M – 94
2016
Q2 		$17.5M Buy
+50,000
New +$19.3M 0.36% 19

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artal Group's REGN Position: Q3 2016 in Review

Artal Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 50,000 shares — an estimated $20.1M sold.

Artal Group first reported a position in REGN in Q2 2016 and held it in 1 quarter. The position peaked at $17.5M in Q2 2016. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

  • Artal Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Artal Group sold 50,000 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $20.1M.
  • Artal Group first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Artal Group's Regeneron Pharmaceuticals position peaked at $17.5M in Q2 2016.
  • 553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Artal Group's 13F filing for Q3 2016, filed 14 Nov 2016.